Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Unknown 3Completed 1

Sponsor Class

OTHER 4INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 26CNS 4Gastrointestinal 3Tumor-Agnostic 2Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 4Brain Neoplasms 4

Interventions

Temozolomide 123Radiotherapy 47Bevacizumab 46Lomustine 25Radiation 20Nivolumab 17Irinotecan 16Carboplatin 16Cyclophosphamide 14Granulocyte-Macrophage Colony-Stimulating Factor 13pembrolizumab 11dabrafenib 10Trastuzumab 10Surgical Procedures, Operative 10Capecitabine 10paclitaxel-Angiopep-2 conjugate 8TIC10 compound 8Paclitaxel 8Gemcitabine 8Carmustine 8trametinib 7Topotecan 7IL13-PE38 7Everolimus 7Drug Therapy 7Aminolevulinic Acid 7AZD 6244 73-Iodobenzylguanidine 7fludarabine 6enzastaurin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × icotinib × CNS × Clear all
NCT04058704 2019-08-15

SMART

Betta Pharmaceuticals Co., Ltd.

Phase 3 Unknown
296 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT02726568 2019-02-19

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
30 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT03754530 2018-11-27

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
162 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT01516983 2014-02-17

Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation

Betta Pharmaceuticals Co., Ltd.

Phase 1/2 Completed
15 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡